Clinical trialNCT00094172CompletedPhase 2Interventional

Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment82Multiple Sclerosis

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Patients who have been diagnosed with clinically isolated syndrome (CIS) often develop problems related to the central nervous system, which controls the nerves in the body. Some of these patients may later be diagnosed with multiple sclerosis (MS), a progressive disease of the nervous system. The purpose of this study is to determine if the drug atorvastatin is helpful to CIS patients. Study hypothesis: Early intervention with atorvastatin in patients with CIS will result in a state of immunological tolerance.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Emmanuelle Waubant, MD, PhD
University of California, San Francisco
Study ChairKOL profile →
clinicaltrials.gov ↗
Scott Zamvil, MD, PhD
University of California, San Francisco
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Montreal Neurological Institute
Montreal, Quebec, Canada

United States

Barrow Neurological Institute
Phoenix, Arizona, United States
Keck School of Medicine
Los Angeles, California, United States
University of California, San Francisco
San Francisco, California, United States
Yale Ms Research Center
New Haven, Connecticut, United States
Johns Hopkins
Baltimore, Maryland, United States
Washington University Multiple Sclerosis Center
St Louis, Missouri, United States
Jacobs Neurological Institute
Buffalo, New York, United States
Mount Sinai School of Medicine
New York, New York, United States
University of Rochester
Rochester, New York, United States
Cleveland Clinic Foundation
Cleveland, Ohio, United States
Oregon Health Sciences University
Portland, Oregon, United States
University of Texas Southwestern Medical Center
Dallas, Texas, United States
Virginia Mason Ms Center
Seattle, Washington, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

AtorvastatinPlacebo

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 31 May 2005
Primary completion: 31 May 2009
Completion: 31 May 2009
Last update posted: 28 Apr 2017
Registered enrollment: 82
Registry id: NCT00094172

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.